Rabies Antiserum Market is estimated to be valued at USD 1.32 Bn in 2025 and is expected to reach USD 1.66 Bn in 2032, exhibiting a compound annual growth rate (CAGR) of 3.3% from 2025 to 2032.
Analyst viewpoint:
The global rabies antiserum market is expected to experience steady growth over the forecast period, driven by the rising incidence of rabies globally. The growing population is also working as a major driver as dogs are the primary host and transmitter of rabies virus. Asia Pacific region currently dominates the market due to higher disease prevalence in countries like India, China, and the Philippines. Africa is also estimated to be one of the fastest-growing regional markets. However, a lack of awareness about rabies preventive care, especially in developing nations, can hamper market growth. The high cost of antiserum compared to vaccines is another challenge. Nevertheless, ongoing Research & Development for the development of more effective and low-cost biosimilars will provide huge opportunities in the long run.
Drivers:
The growth of the market is attributed to factors such as the increasing prevalence of rabies, rising awareness about the disease, and the availability of advanced treatment options. For instance, according to the World Health Organization (WHO) data published in 2025, rabies is estimated to cause 59,000 human deaths annually in over 150 countries, with 95% of cases occurring in Africa and Asia. Due to underreporting and uncertain estimates, this number is likely a gross underestimate. The burden of disease is disproportionally borne by rural poor populations, with approximately half of cases attributable to children under 15 years of age.
Additionally, government initiatives to control rabies and improve healthcare infrastructure in developing countries are also expected to drive market growth.
However, the market is also facing challenges such as the high cost of treatment, lack of access to antiserum in remote areas, and the limited shelf life of antiserum products. Furthermore, the increasing adoption of vaccination as a preventive measure for rabies is also expected to limit the growth of the rabies antiserum market.
Fig 1. Global Rabies Antiserum Market Share (%) by Region, 2025
To learn more about this report, Request sample copy
Rabies Antiserum Market Regional Insights
North America is expected to dominate the global rabies antiserum market during the forecast period, with a significant contribution from the U.S. This can be attributed to the high prevalence of rabies in the region and the availability of advanced treatment options. For instance, as per data by the Centers for Disease Control and Prevention in April 2020, approximately 5,000 animal rabies cases are reported annually to the CDC, and more than 90% of those cases occur in wildlife in the U.S. This region holds a substantial percentage of the market share, accounting for approximately 40%.
The Asia Pacific region is expected to witness significant growth during the forecast period, driven by factors such as the high prevalence of rabies in the region, increasing awareness about the disease, and government initiatives to control the disease. India and China are expected to be the major contributors to the growth of the rabies antiserum market in the region. For instance, according to WHO data, India is endemic for rabies, and accounts for 36% of the world’s rabies deaths. The true burden of rabies in India is not fully known, although, as per available information, it causes 18 000-20 000 deaths every year. About 30-60% of reported rabies cases and deaths in India occur in children under the age of 15 years, as bites that occur in children often go unrecognized and unreported. Asia Pacific accounts for approximately 25% of the market share.
Europe is expected to witness moderate growth during the forecast period, driven by factors such as the increasing prevalence of rabies in some parts of the region and the availability of advanced treatment options. However, the market is also facing challenges such as the high cost of treatment and the limited availability of antiserum products. Europe holds around 21% of the market share.
Fig 2. Global Rabies Antiserum Market Share (%) by Type, 2025
To learn more about this report, Request sample copy
Rabies Antiserum Market Drivers:
Rabies Antiserum Market Report Coverage
Report Coverage | Details | ||
---|---|---|---|
Base Year: | 2024 | Market Size in 2025: | USD 1.32 Bn |
Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
Forecast Period 2025 to 2032 CAGR: | 3.3% | 2032 Value Projection: | USD 1.66 Bn |
Geographies covered: |
|
||
Segments covered: |
|
||
Companies covered: |
CSL Behring, Sanofi Pasteur, Grifols S.A., Bharat Serum and Vaccines Ltd., Novartis AG, Kedrion Biopharma Inc., Biogenesis Bago SA, Serum Institute of India Ltd., Haffkine Bio-Pharmaceutical Corporation Ltd., Shanghai Institute of Biological Products Co. Ltd., CNBG (China National Biotec Group) Co. Ltd., Harbin Pharmaceutical Group Co. Ltd., Beijing Tiantan Biological Products Co. Ltd. |
||
Growth Drivers: |
|
||
Restraints & Challenges: |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Rabies Antiserum Market Opportunities:
Rabies Antiserum Market Trends:
Rabies Antiserum Market Restraints:
Recent Developments
New product launches
Top companies in Rabies Antiserum Market
Definition: Rabies antiserum, also known as anti-rabies serum or rabies immunoglobulin, is a specialized medication used for post-exposure prophylaxis against rabies virus infection. It is a concentrated solution containing antibodies specifically targeted against the rabies virus.
Share
Share
About Author
Vipul Patil is a dynamic management consultant with 6 years of dedicated experience in the pharmaceutical industry. Known for his analytical acumen and strategic insight, Vipul has successfully partnered with pharmaceutical companies to enhance operational efficiency, cross broader expansion, and navigate the complexities of distribution in markets with high revenue potential.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Select a License Type
Credibility and Certifications
860519526
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our ClientsUS Reciprocal Tax Impact Analysis On Rabies Antiserum Market
Stay updated on tariff changes with expert insights and timely information